Proteases as therapeutics

Biochemical Journal

Volumn 435, Issue 1, 2011, Pages 1-16

  Craik, Charles S ^a   Page, Michael J ^a   Madison, Edwin L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Catalyst Biosciences   (United States)

Author keywords

Procoagulant; Protease therapy; Protein degradation; Protein engineering; Trypsin fold

Indexed keywords

ACTIVATED PROTEIN C; ALTEPLASE; ANCROD; BAY 86 6150; BLOOD CLOTTING FACTOR 9 COMPLEX; BLOOD CLOTTING FACTOR 9 CONCENTRATE; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BROMELAIN; COLLAGENASE; DESMOTEPLASE; DROTRECOGIN; FUNGAL ENZYME; HIRUDIN; METALLOPROTEINASE; MOD 5023; NN 1731; NN 7128; NN 7129; NN 7999; PANCRELIPASE; PAPAIN; PROLIFNINE; PROLINE SPECIFIC PROLYL ZINC DEPENDENT ENDOPEPTIDASE; PROLYL ENDOPEPTIDASE; PROTEINASE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 9; RECOMBINANT THROMBIN; RECOTHROM; RETEPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; THERMOLYSIN; THROMBIN; TRIZYTEK; TRYPSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; ZENPEP;

ACUTE HEART INFARCTION; ALOPECIA AREATA; BLEEDING; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; BURN; CATHETER THROMBOSIS; CELL PROTECTION; CEREBRAL PALSY; CERVICAL DYSTONIA; CLINICAL EFFECTIVENESS; CYSTIC FIBROSIS; DEBRIDEMENT; DRUG APPROVAL; DRUG CLEARANCE; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; EMBOLISM; ENZYME ENGINEERING; FIBRINOLYSIS; GENE THERAPY; HEADACHE; HEART INFARCTION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MOLECULAR MECHANICS; MUSCLE SPASM; NONHUMAN; OVERACTIVE BLADDER; PAIN; PANCREAS INSUFFICIENCY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN DEGRADATION; REVIEW; SEPSIS; SEPTIC SHOCK; STRABISMUS; STROKE; THROMBOCYTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; THROMBUS; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; HYDROLYSIS; PEPTIDE HYDROLASES; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

HARNESS;

EID: 79952843364     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20100965     Document Type: Review

References (192)

1. Rodriguez, D., Morrison, C. J. and Overall, C. M. (2010) Matrix metalloproteinases: what do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim. Biophys. Acta 1803, 39-54
2. Duffy, M. J., McGowan, P. M. and Gallagher, W. M. (2008) Cancer invasion and metastasis: changing views. J. Pathol. 214, 283-293
3. Overall, C. M. and Blobel, C. P. (2007) In search of partners: linking extracellular proteases to substrates. Nat. Rev. Mol. Cell Biol. 8, 245-257
4. Puente, X. S., Sánchez, L. M., Gutiérrez-Fernández, A., Velasco, G. and López-Otín, C. (2005) A genomic view of the complexity of mammalian proteolytic systems. Biochem. Soc. Trans. 33, 331-334
5. Puente, X. S. and Lopez-Otin, C. (2004) A genomic analysis of rat proteases and protease inhibitors. Genome Res. 14, 609-622 (Pubitemid 38500232)
6. Puente, X. S., Sánchez, L. M., Overall, C. M. and López-Otín, C. (2003) Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 4, 544-558
7. Manning, G., Whyte, D. B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912-1934 (Pubitemid 35425239)
8. Takeda, S., Kadowaki, S., Haga, T., Takaesu, H. and Mitaku, S. (2002) Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett. 520, 97-101 (Pubitemid 34607281)
9. Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J. and Mustelin, T. (2004) Protein tyrosine phosphatases in the human genome. Cell 117, 699-711 (Pubitemid 38748887)
10. Hanna, J. A, Bordeaux, J., Rimm, D. L. and Agarwal, S. (2009) The function, proteolytic processing, and histopathology of Met in cancer. Adv. Cancer Res. 103, 1-23
11. Bergstrom, F. C., Reynolds, S., Johnstone, M., Pike, R. N., Buckle, A. M., Kemp, D. J., Fischer, K. and Blom, A. M. (2009) Scabies mite inactivated serine protease paralogs inhibit the human complement system. J. Immunol. 182, 7809-7817
12. Rawlings, N. D., Tolle, D. P. and Barrett, A. J. (2004) Evolutionary families of peptidase inhibitors. Biochem. J. 378, 705-716 (Pubitemid 38406845)
13. Scott, C. J. and Taggart, C. C. (2010) Biologic protease inhibitors as novel therapeutic agents. Biochimie 92, 1681-1688
14. Overall, C. M. and Dean, R. A. (2006) Degradomics: systems biology of the protease web. Pleiotropic roles of MMPs in cancer. Cancer Metastasis Rev. 25, 69-75
15. Baker, S. S., Borowitz, D., Duffy, L., Fitzpatrick, L., Gyamfi, J. and Baker, R. D. (2005) Pancreatic enzyme therapy and clinical outcomes in patients with cystic fibrosis. J. Pediatr. 146, 189-193
16. Williams, J. R. (1951) The fibrinolytic activity of urine. Br. J. Exp. Pathol. 32, 530-537
17. Medved, L. and Nieuwenhuizen, W. (2003) Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb. Haemostasis 89, 409-419 (Pubitemid 36329229)
18. Weisel, J. W. (2007) Structure of fibrin: impact on clot stability. J. Thromb. Haemostasis 5, 116-124
19. Mosnier, L. O. and Bouma, B. N. (2006) Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler. Thromb. Vasc. Biol. 26, 2445-2453
20. Zhang, L., Gong, Y., Grella, D. K., Castellino, F. J. and Miles, L. A. (2003) Endogenous plasmin converts Glu-plasminogen to Lys-plasminogen on the monocytoid cell surface. J. Thromb. Haemostasis 1, 1264-1270
21. Blasi, F. and Carmeliet, P. (2002) uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell Biol. 3, 932-943
22. Dass, K., Ahmad, A., Azmi, A. S., Sarkar, S. H. and Sarkar, F. H. (2008) Evolving role of uPA/uPAR system in human cancers. Cancer Treat. Rev. 34, 122-136
23. Dillon, P. W., Jones, G. R., Bagnall-Reeb, H. A., Buckley, J. D., Wiener, E. S. and Haase, G. M. (2004) Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study. J. Clin. Oncol. 22, 2718-2723
24. Rijken, D. C. and Lijnen, H. R. (2009) New insights into the molecular mechanisms of the fibrinolytic system. J Thromb. Haemostasis 7, 4-13
25. Hoylaerts, M., Rijken, D. C., Lijnen, H. R. and Collen, D. (1982) Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol. Chem. 257, 2912-2919 (Pubitemid 12118804)
26. Andreasen, P. A., Egelund, R. and Petersen, H. H. (2000) The plasminogen activation system in tumor growth, invasion, and metastasis. Cell. Mol. Life Sci. 57, 25-40
27. Bode, C., Smalling, R. W., Berg, G., Burnett, C., Lorch, G., Kalbfleisch, J. M., Chernoff, R., Christie, L. G., Feldman, R. L., Seals, A. A. and Weaver, W. D. (1996) Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 94, 891-898
28. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) investigators (1997) A comparison of reteplase with alteplase for acute myocardial infarction. N. Engl. J. Med. 337, 1118-1123
29. Semba, C. P., Sugimoto, K. and Razavi, M. K. (2001) Alteplase and tenecteplase: applications in the peripheral circulation. Tech. Vasc. Interv. Radiol. 4, 99-106
30. Madison, E. L., Goldsmith, E. J., Gerard, R. D., Gething, M. J. and Sambrook, J.F. (1989) Serpin-resistant mutants of human tissue-type plasminogen activator. Nature 339, 721-724 (Pubitemid 19175360)
31. Smalling, R. W. (1996) Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am. J. Cardiol. 78, 2-7
32. van de Werf, F., Cannon, C. P., Luyten, A., Houbracken, K., McCabe, C. H., Berioli, S., Bluhmki, E., Sarelin, H., Wang-Clow, F., Fox, N. L. and Braunwald, E. (1999) Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 Investigators. Am. Heart J. 137, 786-791
33. Cannon, C. P., Gibson, C. M., McCabe, C. H., Adgey, A. A., Schweiger, M. J., Sequeira, R. F., Grollier, G., Giugliano, R. P., Frey, M. and Mueller, H.S. (1998) TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation 98, 2805-2814 (Pubitemid 29003960)
34. van de Werf, F., Adgey, J., Ardissino, D., Armstrong, P. W., Aylward, P., Barbash, G., Betriu, A., Binbrek, A. S., Califf, R. and Diaz, R. (1999) Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 354, 716-722 (Pubitemid 29405785)
35. Kunamneni, A., Abdelghani, T. T. and Ellaiah, P. (2007) Streptokinase: the drug of choice for thrombolytic therapy. J. Thromb. Thrombolysis 23, 9-23
36. Ueshima, S. and Matsuo, O. (2006) Development of new fibrinolytic agents. Curr. Pharm. Des. 12, 849-857
37. Howard, E. L., Becker, K. C., Rusconi, C. P. and Becker, R. C. Factor IXa inhibitors as novel anticoagulants. Arterioscler. Thromb. Vasc. Biol. 27, 722-727
38. Eley, R. C., Green, A. A. and McKhann, C. F. (1936) The use of a blood coagulant from the human placenta in the treatment of haemophilia. J. Pediatr. 8, 13
39. Pipe, S. W. and Kaufman, R. J. (2000) A chamber of hope for haemophilia. Nat. Biotechnol. 18, 264-265
40. Monahan, P. E. and Di Paola, J. (2010) Recombinant Factor IX for clinical and research use. Semin. Thromb. Hemostasis 36, 498-509
41. Stafford, D. W. (2005) The vitamin K cycle. J. Thromb. Haemostasis 3, 1873-1878
42. Di Scipio, R. G. and Davie, E. W. (1979) Characterization of protein S, a γ-carboxyglutamic acid containing protein from bovine and human plasma. Biochemistry 18, 899-904
43. McMullen, B. A., Fujikawa, K. and Kisiel, W. (1983) The occurrence of β-hydroxyaspartic acid in the vitamin K-dependent blood coagulation zymogens. Biochem. Biophys. Res. Commun. 115, 8-14
44. Di Scipio, R. G., Kurachi, K. and Davie, E. W. (1978) Activation of human Factor IX (Christmas factor). J. Clin. Invest. 61, 1528-1538
45. Kurachi, K. and Davie, E. W. (1982) Isolation and characterization of a cDNA coding for human Factor IX. Proc. Natl. Acad. Sci. U.S.A. 79, 6461-6464
46. Gavino, A. C. P. (2007) A 5-month-old male with an isolated prolonged partial thromboplastin time. Lab. Med. 38, 218-221
47. Oldenburg, J. and Pavlova, A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia 12, 15-22
48. Ljung, R., Petrini, P., Tengborn, L. and Sjörin, E. (2001) Haemophilia B mutations in Sweden: a population-based study of mutational heterogeneity. Br. J. Haematol. 113, 81-86
49. Mannucci, P. M. (2008) Back to the future: a recent history of haemophilia treatment. Haemophilia 14, 10-18
50. McVey, J. H., Boswell, E., Mumford, A. D., Kemball-Cook, G. and Tuddenham, E.G. (2001) Factor VII deficiency and the FVII mutation database. Hum. Mutat. 17, 3-17
51. D'Angelo, M. R. and Dutton, R. P. (2010) Management of trauma-induced coagulopathy: trends and practices. AANA J. 78, 35-40
52. Franchini, M., Montagnana, M., Targher, G., Zaffanello, M. and Lippi, G. (2008) The use of recombinant Factor VIIa in liver diseases. Blood Coagul. Fibrinolysis 19, 341-348
53. Lisman, T., Moschatsis, S., Adelmeijer, J., Nieuwenhuis, H. K. and de Groot, P. G. (2003) Recombinant Factor VIIa enhances deposition of platelets with congenital or acquired α IIb β 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. Blood 101, 1864-1870
54. Laurian, Y. (2002) Treatment of bleeding in patients with platelet disorders: is there a place for recombinant Factor VIIa? Pathophysiol. Haemostasis Thromb. 32, 37-40
55. Friederich, P. W., Henny, C. P., Messelink, E. J., Geerdink, M. G., Keller, T., Kurth, K. H., Büller, H. R. and Levi, M. (2003) Effect of recombinant activated Factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 361, 201-205 (Pubitemid 36126219)
56. Woodruff, S. I., Dougherty, A. L., Dye, J. L., Mohrle, C. R. and Galarneau, M. R. (2010) Use of recombinant Factor VIIA for control of combat-related haemorrhage. Emerg. Med. J. 27, 121-124
57. Boffard, K. D., Riou, B., Warren, B., Choong, P.I., Rizoli, S., Rossaint, R., Axelsen, M. and Kluger, Y. (2005) Recombinant Factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J. Trauma 59, 8-15
58. Shapiro, A. D., Gilchrist, G. S., Hoots, W. K., Cooper, H. A. and Gastineau, D. A. (1998) Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb. Haemostasis 80, 773-778
59. Kemball-Cook, G., Johnson, D. J., Tuddenham, E. G. and Harlos, K. (1999) Crystal structure of active site-inhibited human coagulation Factor VIIa (des-Gla). J. Struct. Biol. 127, 213-223
60. Rand, K. D., Andersen, M. D., Olsen, O. H., Jørgensen, T. J., Ostergaard, H., Jensen, O. N., Stennicke, H. R. and Persson, E. (2008) The origins of enhanced activity in Factor VIIa analogs and the interplay between key allosteric sites revealed by hydrogen exchange mass spectrometry. J. Biol. Chem. 283, 13378-13387
61. 2+ sites in Factor VIIa. J. Biol. Chem. 281, 24873-24888
62. Banner, D. W., D'Arcy, A., Chène, C., Winkler, F. K., Guha, A., Konigsberg, W. H., Nemerson, Y. and Kirchhofer, D. (1996) The crystal structure of the complex of blood coagulation Factor VIIa with soluble tissue factor. Nature 380, 41-46 (Pubitemid 26076234)
63. Sichler, K., Banner, D. W., D'Arcy, A., Hopfner, K.P., Huber, R., Bode, W., Kresse, G. B., Kopetzki, E. and Brandstetter, H. (2002) Crystal structures of uninhibited Factor VIIa link its cofactor and substrate-assisted activation to specific interactions. J. Mol. Biol. 322, 591-603
64. Di Cera, E. (2008) Thrombin. Mol. Aspects Med. 29, 203-254
65. Coughlin, S. R. (2005) Protease-activated receptors in haemostasis, thrombosis and vascular biology. J. Thromb. Haemostasis 3, 1800-1814
66. Di Cera, E. (2007) Thrombin as procoagulant and anticoagulant. J. Thromb. Haemostasis 5, 196-202
67. van de Locht, A., Stubbs, M. T., Bauer, M. and Bode, W. (1996) Crystallographic evidence that the F2 kringle catalytic domain linker of prothrombin does not cover the fibrinogen recognition exosite. J. Biol. Chem. 271, 3413-3416
68. Chapman, W. C., Singla, N., Genyk, Y., McNeil, J. W., Renkens, Jr, K. L., Reynolds, T. C., Murphy, A. and Weaver, F. A. (2007) A Phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical haemostasis. J. Am. Coll. Surg. 205, 256-265
69. Bowman, L. J., Anderson, C. D. and Chapman, W. C. (2010) Topical recombinant human thrombin in surgical haemostasis. Semin. Thromb. Hemostasis 36, 477-484
70. Yan, S. B., Helterbrand, J. D., Hartman, D. L., Wright, T. J. and Bernard, G. R. (2001) Low levels of protein C are associated with poor outcome in severe sepsis. Chest 120, 915-922
71. Esmon, C. T. (2006) Inflammation and the activated protein C anticoagulant pathway. Semin. Thromb. Hemostasis 32, 49-60
72. Esmon, C. T., Fukudome, K., Mather, T., Bode, W., Regan, L. M., Stearns-Kurosawa, D. J. and Kurosawa, S. (1999) Inflammation, sepsis, and coagulation. Haematologica 84, 254-259 (Pubitemid 29476931)
73. Mather, T., Oganessyan, V., Hof, P., Huber, R., Foundling, S., Esmon, C. and Bode, W. (1996) The 2.8 Å crystal structure of Gla-domainless activated protein C. EMBO J. 15, 6822-6831
74. Esmon, C. T. (1989) The roles of protein C and thrombomodulin in the regulation of blood coagulation. J. Biol. Chem. 264, 4743-4746
75. Kisiel, W. (1979) Human plasma protein C: isolation, characterization, and mechanism of activation by α-thrombin. J. Clin. Invest. 64, 761-769
76. Esmon, C. T. (2006) The endothelial protein C receptor. Curr. Opin. Hematol. 13, 382-385
77. Riewald, M., Petrovan, R. J., Donner, A., Mueller, B. M. and Ruf, W. (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296, 1880-1882 (Pubitemid 34596276)
78. Joyce, D. E., Gelbert, L., Ciaccia, A., DeHoff, B. and Grinnell, B. W. (2001) Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J. Biol. Chem. 276, 11199-11203, 2001
79. Nakanishi-Matsui, M., Zheng, Y. W., Sulciner, D. J., Weiss, E. J., Ludeman, M. J. and Coughlin, S. R. (2000) PAR3 is a cofactor for PAR4 activation by thrombin. Nature 404, 609-613
80. Yang, X. V., Banerjee, Y., Fernández, J. A., Deguchi, H., Xu, X., Mosnier, L. O., Urbanus, R. T., de Groot, P. G., White-Adams, T. C., McCarty, O. J. and Griffin, J. H. (2009) Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc. Natl. Acad. Sci. U.S.A. 106, 274-279
81. Elphick, G. F., Sarangi, P. P., Hyun, Y. M., Hollenbaugh, J. A., Ayala, A., Biffl, W. L., Chung, H. L., Rezaie, A. R., McGrath, J. L., Topham, D. J. et al. (2009) Recombinant human activated protein C inhibits integrin-mediated neutrophil migration. Blood 113, 4078-4085
82. Dellinger, R. P. (2008) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med. 34, 17-60
83. Bernard, G. R., Vincent, J. L., Laterre, P. F., LaRosa, S. P., Dhainaut, J. F., Lopez-Rodriguez, A., Steingrub, J. S., Garber, G. E., Helterbrand, J. D., Ely, E. W. et al. (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709
84. Abraham, E., Laterre, P. F., Garg, R., Levy, H., Talwar, D., Trzaskoma, B. L., François, B., Guy, J. S., Brückmann, M., Rea-Neto, A. et al. (2005) Drotrecogin α (activated) for adults with severe sepsis and a low risk of death. N. Engl. J. Med. 353, 1332-1341
85. Nilsson, G., Hojgard, S. and Berntorp, E. (2010) Treatment of the critically ill patient with protein C: is it worth the cost? Thromb. Res. 125, 494-500
86. Toussaint, S. and Gerlach, H. (2009) Activated protein C for sepsis. N. Engl. J. Med. 361, 2646-2652
87. Bernard, G. R., Ely, E. W., Wright, T. J., Fraiz, J., Stasek, Jr, J. E., Russell, J. A., Mayers, I., Rosenfeld, B. A., Morris, P. E., Yan, S. B. and Helterbrand, J.D. (2001) Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit. Care Med. 29, 2051-2059
88. Gentry, C. A., Gross, K. B., Sud, B. and Drevets, D. A. (2009) Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Crit. Care Med. 37, 19-25
89. Schiavo, G., Matteoli, M. and Montecucco, C. (2000) Neurotoxins affecting neuroexocytosis. Physiol. Rev. 80, 717-766
90. Keller, J. E. (2006) Recovery from botulinum neurotoxin poisoning in vivo. Neuroscience 139, 629-637
91. Ravichandran, E., Gong, Y., Al Saleem, F. H., Ancharski, D. M., Joshi, S. G. and Simpson, L. L. (2006) An initial assessment of the systemic pharmacokinetics of botulinum toxin. J. Pharmacol. Exp. Ther. 318, 1343-1351
92. Scott, A. B. (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87, 1044-1049
93. Truong, D. D., Stenner, A. and Reichel, G. (2009) Current clinical applications of botulinum toxin. Curr. Pharm. Des. 15, 3671-3680
94. Dressler, D. (2008) Botulinum toxin drugs: future developments. J. Neural Transm. 115, 575-577
95. Chen, S. and Barbieri, J. T. (2009) Engineering botulinum neurotoxin to extend therapeutic intervention. Proc. Natl. Acad. Sci. U.S.A 106, 9180-9184
96. Wooldridge, J. L., Heubi, J. E., Amaro-Galvez, R., Boas, S. R., Blake, K. V., Nasr, S. Z., Chatfield, B., McColley, S. A., Woo, M. S., Hardy, K. A. et al. (2009) EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency. J. Cystic Fibrosis 8, 405-417
97. Littlewood, J. M., Wolfe, S. P. and Conway, S. P. (2006) Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatr. Pulmonol. 41, 35-49
98. Ramundo, J. and Gray, M. (2008) Enzymatic wound debridement. J. Wound Ostomy Continence Nurs. 35, 273-280
99. Klasen, H. J. (2000) A review on the nonoperative removal of necrotic tissue from burn wounds. Burns 26, 207-222
100. Keyt, B. A., Paoni, N. F. and Bennett, W. F. (1996) Site-directed mutagenesis of tissue-type plasminogen activator. In Protein Engineering: Principles and Practice (Cleland, J. L. and Craik, C.S., eds), pp. 435-466, Wiley-Liss, New York
101. van de Werf, F. J. (1999) The ideal fibrinolytic: can drug design improve clinical results? Eur. Heart J. 20, 1452-1458
102. Liberatore, G. T., Samson, A., Bladin, C., Schleuning, W. D. and Medcalf, R. L. (2003) Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 34, 537-543
103. Tebbe, U., Bramlage, P., Graf, A., Lechleitner, P., Bode, C., Riess, F. C., Clemens, N., Al-Rawi, Y., Konstantinides, S. and Goldhaber, S. Z. (2009) Desmoteplase in acute massive pulmonary thromboembolism. Thromb. Haemostasis 101, 557-562
104. Malcolm, A. D., Keltai, M. and Walsh, M. J. (1996) ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction. Eur. Heart J. 17, 1522-1531
105. Inoue, T., Nishiki, R., Kageyama, M. and Node, K. (2005) Therapeutic potential of monteplase in acute myocardial infarction. Am. J. Cardiovasc. Drugs 5, 225-231
106. Monrad, E. S. (1991) Thrombolysis: the need for a critical review. J. Am. Coll. Cardiol. 18, 1573-1578
107. Ambrus, J. L., Ambrus, C. M., Back, N., Sokal, J. E. and Collins, G. L. (1957) Clinical and experimental studies on fibrinolytic enzymes. Ann. N.Y. Acad. Sci. 68, 97-136
108. Marder, V. J., Landskroner, K., Novokhatny, V., Zimmerman, T. P., Kong, M., Kanouse, J. J. and Jesmok, G. (2001) Plasmin induces local thrombolysis without causing haemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb. Haemostasis 86, 739-745 (Pubitemid 32834181)
109. Marder, V. J. and Novokhatny, V. (2010) Direct fibrinolytic agents: biochemical attributes, preclinical foundation and clinical potential. J. Thromb. Haemostasis 8, 433-444
110. Di Nisio, M., Middeldorp, S. and Buller, H. R. (2005) Direct thrombin inhibitors. N. Engl. J. Med. 353, 1028-1040
111. Koh, C. Y. and Kini, R. M. (2009) Molecular diversity of anticoagulants from haematophagous animals. Thromb. Haemostasis 102, 437-453
112. Yu, X., Xia, X., Fang, H., Zhou, C. and Chen, H. (2007) Expression and purification of ancrod, an anticoagulant drug, in Pichia pastoris. Protein Expression Purif. 55, 257-261 (Pubitemid 47369666)
113. Levy, D. E., del Zoppo, G. J., Demaerschalk, B. M., Demchuk, A. M., Diener, H. C., Howard, G., Kaste, M., Pancioli, A. M., Ringelstein, E. B., Spatareanu, C. and Wasiewski, W. W. (2009) Ancrod in acute ischemic stroke: results of 500 subjects beginning treatment within 6 hours of stroke onset in the ancrod stroke program. Stroke 40, 3796-3803
114. Randolph, A., Chamberlain, S. H., Chu, H. L., Retzios, A. D., Markland, Jr, F. S. and Masiarz, F. R. (1992) Amino acid sequence of fibrolase, a direct-acting fibrinolytic enzyme from Agkistrodon contortrix contortrix venom. Protein Sci. 1, 590-600
115. Shah, A. R. and Scher, L. (2007) Drug evaluation: alfimeprase, a plasminogenin-dependent thrombolytic. IDrugs 10, 329-335
116. Jespers, L., Vanwetswinkel, S., Lijnen, H. R., van Herzeele, N., van Hoef, B., Demarsin, E., Collen, D. and De Maeyer, M. (1999) Structural and functional basis of plasminogen activation by staphylokinase. Thromb. Haemostasis 81, 479-485 (Pubitemid 29178926)
117. Vanderschueren, S., Barrios, L., Kerdsinchai, P., Van Den Heuvel, P., Hermans, L., Vrolix, M., De Man, F., Benit, E., Muyldermans, L. and Collen, D. (1995) A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 92, 2044-2049
118. Luisetti, M., Piccioni, P. D., Dyne, K., Donnini, M., Bulgheroni, A., Pasturenzi, L., Donnetta, A. M. and Peona, V. (1991) Some properties of the alkaline proteinase from Aspergillus melleus. Int. J. Tissue React. 13, 187-192
119. Sollid, L. M. (2002) Coeliac disease: dissecting a complex inflammatory disorder. Nat. Rev. Immunol. 2, 647-655
120. Shan, L., Molberg, Ø., Parrot, I., Hausch, F., Filiz, F., Gray, G. M., Sollid, L. M. and Khosla, C. (2002) Structural basis for gluten intolerance in celiac sprue. Science 297, 2275-2279
121. Chen, Y. S., Christensen, J. E., Broadbent, J. R. and Steele, J. L. (2003) Identification and characterization of Lactobacillus helveticus PepO2, an endopeptidase with post-proline specificity. Appl. Environ. Microbiol. 69, 1276-1282
122. Vora, H., McIntire, J., Kumar, P., Deshpande, M. and Khosla, C. (2007) A scaleable manufacturing process for pro-EP-B2, a cysteine protease from barley indicated for celiac sprue. Biotech. Bioeng. 98, 177-185
123. Lollar, P. (2000) Mapping factor VIII inhibitor epitopes using hybrid human/porcine factor VIII molecules. Haematologica 85, 26-28
124. Bhana, N. and Spencer, C. M. (2000) Lanoteplase. BioDrugs 13, 217-224
125. Huntington, J. A., Read, R. J. and Carrell, R. W. (2000) Structure of a serpin - protease complex shows inhibition by deformation. Nature 407, 923-926
126. Lomas, D. A., Evans, D. L., Finch, J. T. and Carrell, R. W. (1992) The mechanism of Z α1-antitrypsin accumulation in the liver. Nature 357, 605-607
127. Higgins, P. J., Ryan, M. P. and Providence, K. M. (1994) Induced expression of p52(PAI-1) in normal rat kidney cells by the microfilament- disrupting agent cytochalasin D. J. Cell Physiol. 159, 187-195
128. Cao, C., Lawrence, D. A., Li, Y., von Arnim, C. A., Herz, J., Su, E. J., Makarova, A., Hyman, B. T., Strickland, D. K. and Zhang, L. (2006) Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J. 25, 1860-1870
129. Jensen, J. K., Dolmer, K. and Gettins, P. G. (2009) Specificity of binding of the low density lipoprotein receptor-related protein to different conformational states of the clade E serpins plasminogen activator inhibitor-1 and proteinase nexin-1. J. Biol. Chem. 284, 17989-17997
130. Guimond, S. and Turnbull, J. E. (2004) Proteoglycans make the grade-ient. Mol. Cell 16, 159-160
131. Gibbs, C. S., Coutré, S. E., Tsiang, M., Li, W. X., Jain, A. K., Dunn, K. E., Law, V. S., Mao, C. T., Matsumura, S. Y. and Mejza, S. J. (1995) Conversion of thrombin into an anticoagulant by protein engineering. Nature 378, 413-416
132. Bah, A., Carrell, C. J., Chen, Z., Gandhi, P. S. and Di Cera, E. Stabilization of the E* form turns thrombin into an anticoagulant. J. Biol. Chem. 284, 20034-20040
133. + binding to thrombin. J. Biol. Chem. 281, 40049-40056
134. + in enzyme function. Physiol. Rev. 86, 1049-1092
135. + activates thrombin. J. Biol. Chem. 284, 36175-36185
136. Marino, F., Pelc, L. A., Vogt, A., Gandhi, P. S. and Di Cera, E. (2010) Engineering thrombin for selective specificity toward protein C and PAR1. J. Biol. Chem. 285, 19145-19152
137. +-activated trypsin. J. Mol. Biol. 378, 666-672
138. Page, M. J. and Di Cera, E. (2010) Combinatorial enzyme design probes allostery and cooperativity in the trypsin fold. J. Mol. Biol. 399, 306-319
139. Gruber, A., Cantwell, A. M., Di Cera, E. and Hanson, S. R. (2002) The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo. J. Biol. Chem. 277, 27581-27584
140. Berny, M. A., White, T. C., Tucker, E. I., Bush-Pelc, L. A., Di Cera, E., Gruber, A. and McCarty, O. J. (2008) Thrombin mutant W215A/E217A acts as a platelet GPIb antagonist. Arterioscler. Thromb. Vasc. Biol. 28, 329-334
141. Kenet, G., Lubetsky, A., Luboshitz, J. and Martinowitz, U. (2003) A new approach to treatment of bleeding episodes in young haemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven). J. Thromb. Haemostasis 1, 450-455
142. Persson, E., Bolt, G., Steenstrup, T. D. and Ezban, M. (2010) Recombinant coagulation factor VIIa: from molecular to clinical aspects of a versatile haemostatic agent. Thromb. Res. 125, 483-489
143. Weimer, T., Wormsbächer, W., Kronthaler, U., Lang, W., Liebing, U. and Schulte, S. (2008) Prolonged in vivo half-life of factor VIIa by fusion to albumin. Thromb. Haemostasis 99, 659-667 (Pubitemid 351694221)
144. Chuang, V. T., Kragh-Hansen, U. and Otagiri, M. (2002) Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res. 19, 569-577
145. Duttaroy, A., Kanakaraj, P., Osborn, B. L., Schneider, H., Pickeral, O. K., Chen, C., Zhang, G., Kaithamana, S., Singh, M., Schulingkamp, R. et al. (2005) Development of a long-acting insulin analog using albumin fusion technology. Diabetes 54, 251-258 (Pubitemid 40105120)
146. Sung, C., Nardelli, B., LaFleur, D. W., Blatter, E., Corcoran, M., Olsen, H. S., Birse, C. E., Pickeral, O. K., Zhang, J., Shah, D. et al. (2003) An IFN-β-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates. J. Interferon Cytokine Res. 23, 25-36 (Pubitemid 36308059)
147. Osborn, B. L., Sekut, L., Corcoran, M., Poortman, C., Sturm, B., Chen, G., Mather, D., Lin, H. L. and Parry, T. J. (2002) Albutropin: a growth hormone - albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys. Eur. J. Pharmacol. 456, 149-158
148. Sen, P., Ghosh, S., Ezban, M., Pendurthi, U. R. and Vijaya Mohan Rao, L. (2001) Effect of glycoPEGylation on factor VIIa binding and internalization. Haemophilia 16, 339-348
149. Yatuv, R., Dayan, I., Carmel-Goren, L., Robinson, M., Aviv, I., Goldenberg-Furmanov, M. and Baru, M. (2008) Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia 14, 476-483 (Pubitemid 351638733)
150. Neuenschwander, P. F. and Morrissey, J.H. (1994) Roles of the membrane-interactive regions of factor VIIa and tissue factor. The factor VIIa Gla domain is dispensable for binding to tissue factor but important for activation of factor X. J. Biol. Chem. 269, 8007-8013
151. Allen, G. A., Persson, E., Campbell, R. A., Ezban, M., Hedner, U. and Wolberg, A. S. (2007) A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of haemophilia. Arterioscler. Thromb. Vasc. Biol. 27, 683-689
152. Persson, E., Kjalke, M. and Olsen, O. H. (2001) Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc. Natl. Acad. Sci. U.S.A. 98, 13583-13588
153. Harvey, S. B., Stone, M. D., Martinez, M. B. and Nelsestuen, G. L. (2003) Mutagenesis of the γ-carboxyglutamic acid domain of human factor VII to generate maximum enhancement of the membrane contact site. J. Biol. Chem. 278, 8363-8369
154. Sarangi, P. P., Lee, H. W. and Kim, M. (2010) Activated protein C action in inflammation. Br. J. Haematol. 148, 817-833
155. Weiler, H. and Kerschen, E. (2009) Modulation of sepsis outcome with variants of activated protein C. J. Thromb. Haemostasis 7, 127-131
156. Loubele, S. T., Spronk, H. M. and Ten Cate, H. (2009) Activated protein C: a promising drug with multiple effects? Mini Rev. Med. Chem. 9, 620-626
157. Berg, D. T., Gerlitz, B., Shang, J., Smith, T., Santa, P., Richardson, M. A., Kurz, K. D., Grinnell, B. W., Mace, K. and Jones, B. E. (2003) Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proc. Natl. Acad. Sci. U.S.A. 100, 4423-4428
158. Brantly, M. L., Wittes, J. T., Vogelmeier, C. F., Hubbard, R. C., Fells, G. A. and Crystal, R. G. (1991) Use of a highly purified α1-antitrypsin standard to establish ranges for the common normal and deficient α1-antitrypsin phenotypes. Chest 100, 703-708
159. Mosnier, L. O., Yang, X. V. and Griffin, J. H. (2007) Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J. Biol. Chem. 282, 33022-33033
160. Yang, L. (2007) Identification of a specific exosite on activated protein C for interaction with protease-activated receptor 1. J. Biol. Chem. 282, 25493-25500
161. Bae, J. S., Yang, L., Manithody, C. and Rezaie, A. R. (2007) Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties. J. Biol. Chem. 282, 9251-9259
162. Harmon, S., Preston, R. J., Ni Ainle, F., Johnson, J.A., Cunningham, M. S., Smith, O. P., White, B. and O'Donnell, J. S. (2008) Dissociation of activated protein C functions by elimination of protein S cofactor enhancement. J. Biol. Chem. 283, 30531-30539
163. Han, M. H., Hwang, S. I., Roy, D. B., Lundgren, D. H., Price, J. V., Ousman, S. S., Fernald, G. H., Gerlitz, B., Robinson, W. H., Baranzini, S. E. et al. (2008) Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451, 1076-1081 (Pubitemid 351317445)
164. Murphy, S. L. and High, K. A. (2008) Gene therapy for haemophilia. Br. J. Haematol. 140, 479-487
165. Slofstra, S. H., Groot, A. P., Maris, N. A., Reitsma, P. H., Cate, H. T. and Spek, C. A. (2006) Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br. J. Pharmacol. 149, 740-746
166. Margaritis, P., Arruda, V. R., Aljamali, M., Camire, R. M.,
167. Margaritis, P. and High, K. A. (2006) Advances in gene therapy using factor VIIa in haemophilia. Semin. Hematol. 43, S101-S104
168. Schneider, H., Mühle, C., Douar, A. M., Waddington, S., Jiang, Q. J., von der Mark, K., Coutelle, C. and Rascher, W. (2002) Sustained delivery of therapeutic concentrations of human clotting factor IX: a comparison of adenoviral and AAV vectors administered in utero. J. Gene Med. 4, 46-53 (Pubitemid 40277155)
169. Graham, T., McIntosh, J., Work, L. M., Nathwani, A. and Baker, A. H. (2008) Performance of AAV8 vectors expressing human factor IX from a hepatic-selective promoter following intravenous injection into rats. Genet. Vaccines Ther. 6, 9
170. +) T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13, 419-422
171. Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B. et al. (2006) Successful transduction of liver in haemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347
172. Rocha, M. and Silva, M. (1951) Bradykinin; mechanism of its release by trypsin and kallikrein. Arch. Int. Pharmacodyn. Ther. 88, 271-282
173. Tu, L., Xu, X., Wan, H., Zhou, C., Deng, J., Xu, G., Xiao, X., Chen, Y., Edin, M. L., Voltz, J. W. et al. (2008) Delivery of recombinant adeno-associated virus-mediated human tissue kallikrein for therapy of chronic renal failure in rats. Hum. Gene Ther. 19, 318-330
174. Bartoli, M., Roudaut, C., Martin, S., Fougerousse, F., Suel, L., Poupiot, J., Gicquel, E., Noulet, F., Danos, O. and Richard, I. (2006) Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. Mol. Ther. 13, 250-259
175. Sleat, D. E., El-Banna, M., Sohar, I., Kim, K. H., Dobrenis, K., Walkley, S. U. and Lobel, P. (2008) Residual levels of tripeptidyl-peptidase I activity dramatically ameliorate disease in late-infantile neuronal ceroid lipofuscinosis. Mol. Genet. Metab. 94, 222-233
176. Sondhi, D., Peterson, D. A., Edelstein, A. M., del Fierro, K., Hackett, N. R. and Crystal, R. G. (2008) Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis. Exp. Neurol. 213, 18-27
177. Muzio, M., Chinnaiyan, A. M., Kischkel, F. C., O'Rourke, K., Shevchenko, A., Ni, J., Scaffidi, C., Bretz, J. D., Zhang, M., Gentz, R. et al. (1996) FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85, 817-827 (Pubitemid 26193033)
178. Lu, Y., Wu, L. Q., Wang, S.G., Lv, Z. H. and Han, B. (2008) Caspase-3 gene transfected with LIGHT gene: can it be used for therapy of human hepatocellular carcinoma? Clin. Chem. Lab. Med. 46, 470-474
179. Komata, T., Kondo, Y., Kanzawa, T., Hirohata, S., Koga, S., Sumiyoshi, H., Srinivasula, S. M., Barna, B. P., Germano, I. M., Takakura, M. et al. (2001) Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res. 61, 5796-5802 (Pubitemid 32769097)
180. Komata, T., Kondo, Y., Kanzawa, T., Ito, H., Hirohata, S., Koga, S., Sumiyoshi, H., Takakura, M., Inoue, M., Barna, B. P. et al. (2002) Caspase-8 gene therapy using the human telomerase reverse transcriptase promoter for malignant glioma cells. Hum. Gene Ther. 13, 1015-1025
181. Takeuchi, H., Kanzawa, T., Kondo, Y., Komata, T., Hirohata, S., Kyo, S. and Kondo, S. (2004) Combination of caspase transfer using the human telomerase reverse transcriptase promoter and conventional therapies for malignant glioma cells. Int. J. Oncol. 25, 57-63
182. Zhang, X., Turner, C. and Godbey, W. T. (2009) Comparison of caspase genes for the induction of apoptosis following gene delivery. Mol. Biotechnol. 41, 236-246
183. Wolan, D. W., Zorn, J. A., Gray, D. C. and Wells, J. A. (2009) Small-molecule activators of a proenzyme. Science 326, 853-858
184. Kurschus, F. C. and Jenne, D. E. (2010) Delivery and therapeutic potential of human granzyme B. Immunol. Rev. 235, 159-171
185. Kakkis, E.D., Muenzer, J., Tiller, G. E., Waber, L., Belmont, J., Passage, M., Izykowski, B., Phillips, J., Doroshow, R., Walot, I. et al. (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344, 182-188
186. Page, M. J. and Di Cera, E. (2008) Evolution of peptidase diversity. J. Biol. Chem. 283, 30010-30014
187. Renatus, M., Engh, R. A., Stubbs, M. T., Huber, R., Fischer, S., Kohnert, U. and Bode, W. (1997) Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA. EMBO J. 16, 4797-4805
188. Paoni, N. F., Chow, A. M., Peña, L. C., Keyt, B. A., Zoller, M. J. and Bennett, W. F. (1993) Making tissue-type plasminogen activator more fibrin specific. Protein Eng. 6, 529-534
189. Page, M. J., Macgillivray, R. T. and Di Cera, E. (2005) Determinants of specificity in coagulation proteases. J. Thromb. Haemostasis 3, 2401-2408 (Pubitemid 41727155)
190. Eastman, D., Wurm, F. M., van Reis, R. and Higgins, D. L. (1992) A region of tissue plasminogen activator that affects plasminogen activation differentially with various fibrin(ogen)-related stimulators. Biochemistry 31, 419-422
191. Carter, W. J., Myles, T., Gibbs, C. S., Leung, L. L. and Huntington, J. A. (2004) Crystal structure of anticoagulant thrombin variant E217K provides insights into thrombin allostery. J. Biol. Chem. 279, 26387-26394
192. Perona, J. J. and Craik, C.S. (1997) Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J. Biol. Chem. 272, 29987-29990